Insider trading

Period: 120 months Stock: INCY Minimum amount: $1M × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

76 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

76 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

76 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

76 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
76 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
76 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

76 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
15 Sep 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan 2×
$2.80M 23,218 at 120.49
11.2%
Planned (10b5-1)
19 Aug 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.36M 10,801 at 125.56
5.6%
Planned (10b5-1)
12 Aug 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.30M 10,803 at 120.04
5.3%
Planned (10b5-1)
5 Aug 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.31M 10,640 at 122.69
4.9%
Planned (10b5-1)
31 Jul 2026
Mayes Patrick A EVP & Chief Scientific Officer
Sold on a plan 11×
$5.01M 41,899 at 119.46
40.5%
Planned (10b5-1)
31 Jul 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.90M 15,888 at 119.70
6.9%
Planned (10b5-1)
15 Jul 2026
Stein Steven H CMO & Head of Late-Stage Dev.
Sold on a plan
$3.19M 28,237 at 113.05
52.0%
Sold half or more
19 May 2026
Clancy Paul J Director
Sold on a plan
$1.42M 15,000 at 94.93
38.7%
Planned (10b5-1)
17 Apr 2026
CAGNONI PABLO J President, Global Head of R&D
Sold on a plan
$1.80M 18,667 at 96.50
6.6%
Planned (10b5-1)
17 Mar 2026
CAGNONI PABLO J President, R&D
Sold on a plan
$1.76M 18,667 at 94.24
7.4%
Planned (10b5-1)
19 Feb 2026
CAGNONI PABLO J President, R&D
Sold on a plan
$1.88M 18,668 at 100.91
7.4%
Planned (10b5-1)
7 Jan 2026
Issa Mohamed Khairie EVP, Head of US Oncology
Sold on a plan
$1.18M 10,856 at 109.07
14.1%
Planned (10b5-1)
5 Jan 2026
Stein Steven H EVP & Chief Medical Officer
Sold on a plan
$1.59M 15,634 at 101.70
31.4%
Planned (10b5-1)
16 Dec 2025
Morrissey Michael James EVP, Head of Tech. Operations
Sold on a plan 2×
$5.25M 54,008 at 97.29
62.9%
Sold half or more
2 Dec 2025
Stein Steven H EVP & Chief Medical Officer
Sold on a plan
$2.06M 20,105 at 102.51
24.2%
Planned (10b5-1)
10 Nov 2025
Hoppenot Herve Director
Sold on a plan
$19.77M 187,500 at 105.46
36.3%
Planned (10b5-1)
14 Jul 2025
Stein Steven H EVP & Chief Medical Officer
Sold on a plan
$1.02M 14,952 at 68.47
13.3%
Planned (10b5-1)
14 Mar 2025
Flannelly Barry P EVP & General Manager US
Sold on a plan 3×
$1.34M 19,807 at 67.69
37.1%
Planned (10b5-1)
26 Feb 2025
Denton Sheila A. EVP & General Counsel
Sold on a plan 2×
$1.04M 14,069 at 74.07
35.2%
Planned (10b5-1)
25 Jul 2024
Iyengar Vijay K EVP, GMAPPS
Sold on a plan
$1.09M 15,571 at 70.00
29.8%
Planned (10b5-1)
12 Jun 2024
Flannelly Barry P EVP & General Manager US
Sold on a plan
$1.15M 19,164 at 60.00
22.4%
Planned (10b5-1)
1 Aug 2023
Stein Steven H EVP & Chief Medical Officer
Sold on a plan
$1.36M 21,511 at 63.28
18.1%
Planned (10b5-1)
30 Jan 2023
Pasquale Maria E EVP & General Counsel
Sold, plan not stated 6×
$5.09M 60,024 at 84.74
46.7%
4 Jan 2023
Stein Steven H EVP & Chief Medical Officer
Sold, plan not stated
$2.27M 28,399 at 79.78
20.7%
23 Dec 2022
Iyengar Vijay K EVP, GMAPPS
Sold, plan not stated 4×
$1.40M 17,324 at 80.80
31.4%
8 Apr 2022
Flannelly Barry P EVP & General Manager US
Sold, plan not stated 4×
$3.67M 43,993 at 83.49
40.3%
10 Mar 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 6×
$15.98M 218,563 at 73.13
0.7%
9 Mar 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$5.06M 70,517 at 71.72
0.2%
8 Mar 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$7.07M 100,000 at 70.68
0.3%
22 Feb 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$6.79M 99,800 at 68.07
0.3%
18 Feb 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 4×
$9.10M 133,032 at 68.38
0.4%
17 Feb 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$19.84M 292,972 at 67.74
0.9%
14 Feb 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$33.20M 502,852 at 66.02
1.6%
11 Feb 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$18.48M 276,507 at 66.82
0.9%
10 Feb 2022
BAKER BROS. ADVISORS LP Director · indirect
Bought 3×
$55.28M 819,015 at 67.49
2.6%
17 Dec 2021
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$78.32M 1,075,872 at 72.80
3.6%
Largest buy in 3 yrs
16 Dec 2021
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$12.18M 169,315 at 71.96
0.6%
15 Dec 2021
BAKER BROS. ADVISORS LP Director · indirect
Bought 6×
$25.05M 350,332 at 71.51
1.2%
First buy on file
29 Jun 2021
Wenqing Yao EVP, Head of Discovery Chem
Sold, plan not stated
$2.32M 27,194 at 85.37
22.4%
29 Mar 2021
Morrissey Michael James EVP, Head of Tech. Operations
Sold, plan not stated
$1.62M 20,000 at 81.08
30.6%
23 Feb 2021
Hoppenot Herve Chairman / CEO
Bought
$1.00M 12,925 at 77.37
4.8%
First buy on file
25 Jan 2021
Wenqing Yao EVP, Head of Discovery Chem
Sold, plan not stated 2×
$2.15M 21,545 at 100.00
13.0%
2 Nov 2020
Flannelly Barry P EVP & General Manager US
Sold, plan not stated
$1.73M 20,000 at 86.60
33.3%
27 Aug 2020
DIXON WENDY L Director
Sold, plan not stated
$1.89M 20,000 at 94.51
58.4%
Sold half or more
7 Jul 2020
Hoppenot Herve Chairman / CEO
Sold, plan not stated 2×
$9.87M 89,771 at 110.00
25.2%
7 Jul 2020
Stein Steven H EVP & Chief Medical Officer
Sold, plan not stated 3×
$1.55M 14,159 at 109.56
12.7%
6 Jul 2020
Stein Steven H EVP & Chief Medical Officer
Sold, plan not stated 5×
$3.87M 36,124 at 107.25
26.4%
6 Jul 2020
Wenqing Yao EVP, Head of Discovery Chem
Sold, plan not stated 2×
$1.78M 16,553 at 107.32
9.6%
26 Jun 2020
Hoppenot Herve Chairman / CEO
Sold, plan not stated 2×
$12.78M 124,148 at 102.91
34.0%
14 Apr 2020
Pasquale Maria E EVP & General Counsel
Sold, plan not stated
$1.60M 17,827 at 90.00
43.8%
Showing 1–50 of 76. Page 1 of 2 Older →